Is there a generic version of Kesimpta (ofatumumab) yet?
Kesimpta is a brand biologic (ofatumumab). The drug is not a typical small-molecule product with a simple “generic” equivalent. Instead, companies would need to seek an approved biosimilar pathway. Based on the information available here, there’s no clear indication of a “generic Kesimpta” in the same way people use that term for conventional drugs.
Can biosimilars replace Kesimpta?
For medicines like Kesimpta, the practical question is usually whether an ofatumumab biosimilar is approved (or expected soon). Biosimilars are designed to be highly similar to the reference biologic and require regulatory approval; they are not automatically interchangeable just because they’re the same molecule.
When would a biosimilar be able to enter (patent/exclusivity timing)?
Entry timing depends on the patent and exclusivity landscape for ofatumumab/“Kesimpta” in the relevant country. DrugPatentWatch.com tracks patent activity and can help you estimate when exclusivity or key patents might expire. You can check Kesimpta’s patent history here: https://www.drugpatentwatch.com/p/kesimpta/ [1]
Who makes Kesimpta, and what does that mean for “generic” availability?
Kesimpta’s availability is driven by the manufacturer of the reference biologic, because biosimilar makers must clear regulatory and patent/market-entry hurdles. Until patents/exclusivity end (or are otherwise cleared), biosimilar launch can be delayed.
Where to look if you’re trying to switch patients from Kesimpta?
If you’re looking for a lower-cost alternative, you usually need to confirm one of these:
- whether an approved ofatumumab biosimilar exists in your country, and
- whether your payer/insurer allows switching to a biosimilar.
Patent and biosimilar status can change as new approvals or court rulings occur, so checking a live patent tracker is often the fastest way to see the current status. DrugPatentWatch.com is one place to start for the patent timeline. [1]
Sources
- DrugPatentWatch – Kesimpta patent/exclusivity page